Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2500

1.

A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program-AIM-HY INFORM trial.

Mukhtar O, Cheriyan J, Cockcroft JR, Collier D, Coulson JM, Dasgupta I, Faconti L, Glover M, Heagerty AM, Khong TK, Lip GYH, Mander AP, Marchong MN, Martin U, McDonnell BJ, McEniery CM, Padmanabhan S, Saxena M, Sever PJ, Shiel JI, Wych J, Chowienczyk PJ, Wilkinson IB.

Am Heart J. 2018 May 20;204:102-108. doi: 10.1016/j.ahj.2018.05.006. [Epub ahead of print]

PMID:
30092411
2.

Correction to: Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.

Raparelli V, Pastori D, Pignataro SF, Vestri AR, Pignatelli P, Cangemi R, Proietti M, Davì G, Hiatt WR, Lip GYH, Corazza GR, Perticone F, Violi F, Basili S; ARAPACIS Study Collaborators.

Intern Emerg Med. 2018 Aug 3. doi: 10.1007/s11739-018-1922-y. [Epub ahead of print]

PMID:
30076553
3.

Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients.

Li YG, Lee SR, Choi EK, Lip GY.

Korean Circ J. 2018 Aug;48(8):665-684. doi: 10.4070/kcj.2018.0190. Review.

4.

Secondary stroke prevention and guideline adherent antithrombotic treatment in patients with atrial fibrillation: Insights from the Gulf Survey of atrial fibrillation events (Gulf SAFE).

Miyazawa K, Li YG, Rashed WA, Al Mahmeed W, Shehab A, Zubaid M, Lip GYH.

Int J Cardiol. 2018 Jul 24. pii: S0167-5273(18)33607-6. doi: 10.1016/j.ijcard.2018.07.120. [Epub ahead of print]

PMID:
30064925
5.

Heart Failure and Stroke.

Schumacher K, Kornej J, Shantsila E, Lip GYH.

Curr Heart Fail Rep. 2018 Jul 30. doi: 10.1007/s11897-018-0405-9. [Epub ahead of print] Review.

PMID:
30062623
6.

Stroke risk in female patients with atrial fibrillation: Relationship to current guideline recommendations.

Nielsen PB, Potpara TS, Lip GYH.

Trends Cardiovasc Med. 2018 Jul 12. pii: S1050-1738(18)30132-4. doi: 10.1016/j.tcm.2018.07.003. [Epub ahead of print] Review. No abstract available.

PMID:
30057152
7.

Arrhythmias and cognitive function.

Dagres N, Chao TF, Fenelon G, Lip GYH, Chung MK.

Eur Heart J. 2018 Jul 7;39(26):2446-2447. doi: 10.1093/eurheartj/ehy317. No abstract available.

PMID:
30052860
8.

Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation.

Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V, Orenes-Piñero E, Romiti GF, Romanazzi I, Bai Y, Carmo J, Proietti M, Marín F, Lip GYH.

Am J Cardiol. 2018 Jun 2. pii: S0002-9149(18)31184-6. doi: 10.1016/j.amjcard.2018.05.012. [Epub ahead of print]

PMID:
30049460
9.

Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis.

Telles-Garcia N, Dahal K, Kocherla C, Lip GYH, Reddy P, Dominic P.

Int J Cardiol. 2018 Oct 1;268:143-148. doi: 10.1016/j.ijcard.2018.04.034.

PMID:
30041779
10.

Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: A Danish nationwide cohort study.

Fangel MV, Nielsen PB, Larsen TB, Christensen B, Overvad TF, Lip GYH, Goldhaber SZ, Jensen MB.

Int J Cardiol. 2018 Oct 1;268:137-142. doi: 10.1016/j.ijcard.2018.05.037.

PMID:
30041778
11.

Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial).

Lee TC, Qian M, Lip GYH, Di Tullio MR, Graham S, Mann DL, Nakanishi K, Teerlink JR, Freudenberger RS, Sacco RL, Mohr JP, Labovitz AJ, Ponikowski P, Lok DJ, Estol C, Anker SD, Pullicino PM, Buchsbaum R, Levin B, Thompson JLP, Homma S, Ye S; WARCEF Investigators.

Am J Cardiol. 2018 Jun 4. pii: S0002-9149(18)31196-2. doi: 10.1016/j.amjcard.2018.05.024. [Epub ahead of print]

PMID:
30037426
12.

Sex differences in stroke and major adverse clinical events in patients with atrial fibrillation: A systematic review and meta-analysis of 993,600 patients.

Marzona I, Proietti M, Farcomeni A, Romiti GF, Romanazzi I, Raparelli V, Basili S, Lip GYH, Nobili A, Roncaglioni MC.

Int J Cardiol. 2018 Jul 9. pii: S0167-5273(18)33433-8. doi: 10.1016/j.ijcard.2018.07.044. [Epub ahead of print]

PMID:
30025657
13.

Stroke Prophylaxis After a New Emergency Department Diagnosis of Atrial Fibrillation.

Kea B, Lin AL, Olshansky B, Malveau S, Fu R, Raitt M, Lip GYH, Sun BC.

J Am Coll Cardiol. 2018 Jul 24;72(4):471-472. doi: 10.1016/j.jacc.2018.05.022. No abstract available.

PMID:
30025582
14.

Prognostic implication of monocytes in atrial fibrillation: The West Birmingham Atrial Fibrillation Project.

Shahid F, Rahmat NA, Lip GYH, Shantsila E.

PLoS One. 2018 Jul 18;13(7):e0200373. doi: 10.1371/journal.pone.0200373. eCollection 2018.

15.

Causes of death in Japanese patients with atrial fibrillation: The Fushimi AF Registry.

An Y, Ogawa H, Yamashita Y, Ishii M, Iguchi M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GYH, Akao M; Fushimi AF Registry investigators.

Eur Heart J Qual Care Clin Outcomes. 2018 Jul 18. doi: 10.1093/ehjqcco/qcy033. [Epub ahead of print]

PMID:
30020445
16.

Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on anti-platelet therapy: A modelling analysis using the healthcare system in the Netherlands.

Bennaghmouch N, de Veer AJWM, Mahmoodi BK, Jofre-Bonet M, Lip GYH, Bode K, Ten Berg JM.

Eur Heart J Qual Care Clin Outcomes. 2018 Jul 16. doi: 10.1093/ehjqcco/qcy030. [Epub ahead of print]

PMID:
30016398
17.

Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment.

Di Tullio MR, Qian M, Thompson JLP, Labovitz AJ, Mann DL, Sacco RL, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Lip GYH, Levin B, Mohr JP, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Homma S; WARCEF Investigators.

ESC Heart Fail. 2018 Jul 17. doi: 10.1002/ehf2.12331. [Epub ahead of print]

PMID:
30015405
18.

Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.

Chi G, Kerneis M, Kalayci A, Liu Y, Mehran R, Bode C, Halperin JL, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM.

Am Heart J. 2018 Jun 13;203:17-24. doi: 10.1016/j.ahj.2018.06.003. [Epub ahead of print]

PMID:
30015064
19.

Age Threshold for Ischemic Stroke Risk in Atrial Fibrillation: Cohort Data Covering the Entire Korean Population.

Kim TH, Yang PS, Yu HT, Jang E, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B, Lip GYH.

Stroke. 2018 Jul 16. pii: STROKEAHA.118.021047. doi: 10.1161/STROKEAHA.118.021047. [Epub ahead of print]

PMID:
30012820
20.

Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation.

Law SWY, Lau WCY, Wong ICK, Lip GYH, Mok MT, Siu CW, Chan EW.

J Am Coll Cardiol. 2018 Jul 17;72(3):271-282. doi: 10.1016/j.jacc.2018.04.066. Epub 2018 Jul 9.

PMID:
30012320

Supplemental Content

Support Center